Memory/active T cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma

CONCLUSIONS: ICI plus TKI combination therapy may represent a promising treatment option for metastatic FH-deficient RCC. A memory/active T cell-derived signature is associated with the efficacy of ICI+TKI but necessitates further validation.PMID:38512114 | DOI:10.1158/1078-0432.CCR-23-2760

Source: Clinical Cancer Research - March 21, 2024 Category: Cancer & Oncology Authors: Junru Chen Xu Hu Junjie Zhao Xiaoxue Yin Linmao Zheng Jingjing Guo Jianhui Chen Yongquan Wang Xinan Sheng Haiying Dong Xiaodong Liu Xingming Zhang Jiayu Liang Haolin Liu Jin Yao Jiyan Liu Yali Shen Zhibin Chen Zhengyu He Yaodong Wang Ni Chen Ling Nie Meng Source Type: research